A Phase 3 interventional study of standard of care and radiotherapy + standard of care in Breast Cancer Metastatic, sponsored by Chinese Academy of Medical Sciences. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Chinese Academy of Medical Sciences · Phase 3, Interventional, and Treatment
More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic therapy alone, on survival, local control and toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three factors: visceral metastasis (yes vs.no), number of metastases(≤2 vs. >2), hormone receptor(positive vs. negative). SBRT technique is preferred. During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.
Exclusion Criteria:
standard of care
Drug: standard of care
radiotherapy + standard of care
Drug: standard of care · Radiation: radiotherapy + standard of care
patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT. Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
Progression-free Survival
Time from randomization to disease progression at any site or death.
Time frame: 2 years
Overall Survival
Time from randomization to death from any cause.
Time frame: 2 years
Local control rate
Incidence of tumor control within RT fields during follow up.
Time frame: 2 years
Incidence of toxicities
Incidence of acute and late toxicities from treatment graded according to radiation therapy oncology group (RTOG) radiation injury criteria and National Cancer Institute CTCAE version 4.0
Time frame: 2 years
Quality of Life measured by the Functional Assessment of Cancer Therapy- General (FACT-G)
Assessment of quality of life scores by FACT-G
Time frame: 2 years
Translational exploration
Assessment of circulating tumor cells (CTCs), ctDNA, as prognostic and predictive markers of survival, and for early detection of progression.
Time frame: 2 years
Proportion of acceptable SBRT completion
Proportion of patients who completed SBRT with acceptable dose prescriptions
Time frame: 2 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Academy of Medical Sciences